Deflecting Scepticism, Dr. Reddy’s Pushes For Biosimilar Approvals In Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indian company says it is committed to work with government agencies in complying with regulatory requirements.
You may also be interested in...
Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
Early termination of a large outcomes study of Roche’s CETP inhibitor dalcetrapib raises doubts about others in the class. Some analysts speculate that Eli Lilly may opt not to continue with its evacetrapib, but the company says it remains committed.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.